Loading
Lerociclib is a CDK4/6 inhibitor from G1 Therapeutics developed in China by Genor Biopharma, in a phase 3 trial with letrozole for hormone receptor-positive breast cancer.
G1 Therapeutics designed lerociclib (G1T38) as a CDK4/6 inhibitor that could be taken continuously without a break; it licensed Chinese rights to Genor Biopharma, which runs the phase 3 LEONARDA trials with letrozole or fulvestrant in HR-positive, HER2-negative advanced breast cancer. EQRx briefly held Western rights before returning them.
Inhibits cyclin-dependent kinases 4 and 6, arresting hormone receptor-positive breast cancer cells in G1, the class of palbociclib, ribociclib and abemaciclib. Connects to CDK4/6.
1.Lerociclib slips into a pocket on CDK4/6.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Lerociclib" OR ABSTRACT:"Lerociclib" OR TITLE:"GB491" OR ABSTRACT:"GB491" OR TITLE:"G1T38" OR ABSTRACT:"G1T38") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Lerociclib, not a curated reading list.
Shares HR-positive / HER2-negative breast cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares CDK4/6, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Small-molecule kinase inhibitors and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Small-molecule kinase inhibitors and the tag pipeline.